REFERENCES
- Menichetti F: Current and emerging serious Gram-positive infections. Clin Microbiol Infect 2005; 11 (Suppl. 3): 22-28.
- Martin S, Cunha B. et al. Methicillin resistance in Staphy-lococcus aureus and coagulase negative staphylococci: epide-miological and molecular aspects. Microbiol Immunol 2007; 51: 787–95.
- Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46: 5344–9.
- Karchmer AW. Nosocomial bloodstream infections: or-ganisms, risk factors and implications. Clin Infect Dis 2000; 31: 139–43.
- Darouiche RO. Treatment of infections associated with sur-gical infections. N Engl J Med 2004; 350: 1422–9.
- Pavoni GL, Giannella M, Falcone M, Scorzolini L, Libera-tore M, Carlesimo B, et al. Conservative medical therapy of pro-sthetic joint infections: retrospective analysis of an 8-year experience. Clin Microbiol Infect 2004; 10: 831–7.
- Martino P, Venditti M, Micozzi A, Brandimarte C, Gentile G, Santini C, et al. Efficacy of teicoplanin as antimicrobial treat-ment of severe nosocomial infections caused by gram-positive bacteria: a preliminary study. Antimicrob Agents Chemother 1989; 33: 1329–34.
- Harding I, Sorgel F. Comparative pharmacokinetics of te-icoplanin and vancomycin. J Chemother 2000; 12: 15–20.
- Rowland M. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 1990; 18: 184–209.
- Wilson APR, Grunenberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimi-crob Agents 1994; 4:S1–S30.
- Carbone E, Nacinovich F, Stamboulian D. New therapeu-tic strategies with teicoplanin. Medicina (B Aires) 2002; 62: S25–S29.
- Lazzarini L, Tramarin A, Bragagnolo L, Tositti G, Manfrin V, de Lalla F. Three-times weekly teicoplanin in the outpatient treatment of acute methicillin-resistant staphylococcal os-teomyelitis: a pilot study. J Chemother. 2002; 14: 71–5.
- Graninger W, Presterl E, Wenisch C, Schwameis E, Breyer S, Vukovitch T. Management of serious staphylococcal infections in the outpatient setting. Drugs 1997; 54: 21–28.
- Harding I, MacGowan AP, White LO, Darsley ESR, Reed V. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between predose serum concentrations and out-come. J Antimicrob Chemother 2000; 45: 835–41.
- Rouveix B, Jehl F, Drugeon H, Brumpt I, Caulin E. Ran-domized comparison of serum teicoplanin concentrations fol-lowing daily or alternate daily dosing in healthy adults. Antimicrob Agents Chemother 2004; 48: 2394–9.
- Yoshida M, Matzno S, Namba H, Nishikata M, Matsuyama K. Statistical analysis of the adverse effects of glycopeptide an-tibiotics, based on pharmacokinetics and toxicokinetics (PK/TK). J Infect Chemother 2006; 12: 114–8.
- Lazzeri E, Erba P, Perri M, Tascini C, Doria R, Giorgetti J, et al. Scintigraphic imaging of vertebral osteomyelitis with 111In-Biotin Spine 2008; 33:E198-E204.
- Steckelberg JM, Osmon DR. Prosthetic joint infections. In: Waldvogel FA, Bisno AL, eds Infections associated with in-dwelling medical devices, 3rd edn. Washington DC: American Society for Microbiology, 2000;173–209.
- Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bacteri-cidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006; 42: S13—S24.
- Linares J. The VISA/GISA problem: therapeutic implica-tions. Clin Microbiol Infect 2001; 7: S8–515